Clinical trials of antithrombotics - TrialResults-center.org

Trial	Studied treatment	Control treatment	patients	ROB	Result	NCT
acute coronary syndrome
apixaban
APPRAISE-1 (10mg od), 2009	apixaban	placebo		Exploratory	Negative	NCT00313300
APPRAISE-1 (2.5 mg bid), 2009	apixaban	placebo			Negative	NCT00313300
APPRAISE 2, 2011	apixaban	placebo		Low risk of bias	Negative	NCT00831441
APPRAISE japan ongoing	apixaban	placebo		Exploratory	-	NCT00852397
argatroban
ARGAMI-2, 1998	Argatroban	heparin			-
aspirin
VA-pilot	aspirin	placebo			Negative
ALDUSA-pilot	aspirin	placebo			Negative
VA-main, 1983	aspirin	placebo			Suggesting
Canadian (Aspirin + sulfinpyrazone), 1985	aspirin + sulfinpyrazone	placebo			Negative
Canadian (Aspirin vs PBO), 1985	aspirin	placebo			-
Théroux, 1988	aspirin	placebo			Suggesting
ATACS-pilot, 1990	aspirin	control			Negative
RISC, 1990	aspirin	placebo			Suggesting
atopaxar
LANCELOT ACS	atopaxar	placebo		Exploratory	-
J-LANCELOT, 2010	atopaxar	placebo		Exploratory	-
bivalirudin
BAT (Bittl), 1995	bivalirudin	heparin		Low risk of bias	Suggesting
HERO, 1997	bivalirudin	heparin		Exploratory	Suggesting
PROTECT-TIMI 30, 2006	bivalirudin	eptifibatide + heparin		Exploratory	-	NCT00250471
ACUITY (biva alone vs hep+aGP2b3a), 2006	bivalirudin	heparin + GP2b3a inhibitors			Suggesting	NCT00093158
ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006	bivalirudin + GP2b3a inhibitors	heparin + GP2b3a inhibitors			Negative	NCT00093158
ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007	bivalirudin + GP2b3a inhibitors	heparin + GP2b3a inhibitors			Negative
ACUITY (sub groups PCI, bivalirudin alone) importé, 2007	bivalirudin	heparin + GP2b3a inhibitors			Suggesting
clopidogrel
CURE, 2001	clopidogrel + aspirin	aspirin			Suggesting
CURE (PCI sub study), 2001	clopidogrel	placebo		Exploratory	-
CURRENT OASIS 7 (clopidogrel), 2010	clopidogrel high-dose regimen	clopidogrel standard-dose		Low risk of bias	Negative	NCT00335452
coumadin
ASPECT-2 (coumadin vs aspirin), 2002	coumadin	aspirin			Suggesting
ASPECT-2 (coumadin+asp vs asp), 2002	coumadin	control (on top of aspirin)			Suggesting
dalteparin
FRISC (long term), 1996	dalteparin	placebo (on top of aspirin)		Exploratory	Suggesting
FRISC (short term), 1996	dalteparin	placebo (on top of aspirin)		Low risk of bias	-
FRIC prolonged treatment phase (LWMH vs PBO), 1997	dalteparin	placebo (on top of aspirin)			Negative
FRIC (acute phase LMWH vs UFH), 1997	dalteparin	UFH (on top of aspirin)		Exploratory	Negative
dipyridamol
Prandoni, 1991	aspirin + dipyridamol	placebo			Negative
Efegatran
Klootwijk, 1999	Efegatran	heparin		Exploratory	-
enoxaparin
RESCUE	enoxaparin	unfractionated heparin			-	NCT00077818
ESSENCE, 1997	enoxaparin	UFH (on top of aspirin)			Suggesting
TIMI 11 B (short term), 1998	enoxaparin	UFH (on top of aspirin)			Suggesting
TIMI 11 B (long term), 1998	enoxaparin	UFH (on top of aspirin)			Negative
EVET, 2005	enoxaparin	tinzaparin			Suggesting
SYNERGY, 2005	enoxaparin	UFH (on top of aspirin)			Negative	NCT00043784
INTERACT, 2006	enoxaparin	UFH (on top of aspirin)			Suggesting
fondaparinux
PENTUA, 2004	fondaparinux	enoxaparin			-
OASIS 5, 2006	fondaparinux	enoxaparin			-	NCT00139815
hirudin
HELVETICA (Serruys), 1995	Hirudin	heparin		Low risk of bias	-
TIMI 9B, 1996	Hirudin	heparin		Risk of bias	-
GUSTO IIB, 1996	Hirudin	heparin		Risk of bias	-
OASIS pilot, 1997	Hirudin	heparin		Exploratory	-
OASIS, 1997	Hirudin	heparin		Risk of bias	-
HIT-4, 1999	Hirudin	heparin		Exploratory	-
OASIS 2, 1999	Hirudin	heparin		Low risk of bias	-
inogatran
TRIM, 1997	Inogatran	heparin		Exploratory	-
nadroparin
FRAXIS (6days), 1998	nadroparin	UFH (on top of aspirin)		Low risk of bias	Negative
FRAXIS (14 days), 1998	nadroparin	UFH (on top of aspirin)			Negative
otamixaban
SEPIA-ACS1 TIMI 42, 2009	otamixaban	unfractionated heparin		Exploratory	Suggesting	NCT00317395
prasugrel
TRITON-TIMI 38, 2007	prasugrel	clopidogrel		Low risk of bias	Suggesting	NCT00097591
TRILOGY ACS (overall population), 2012	prasugrel	clopidogrel		Low risk of bias	Negative	NCT00699998
ACAPULCO ongoing	prasugrel	clopidogrel			-
rivaroxaban
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011	rivaroxaban 2.5mg	placebo		Low risk of bias	Suggesting	NCT00809965
ATLAS ACS 2 - TIMI 51 (5mg), 2011	rivaroxaban 5mg	placebo			Suggesting	NCT00809965
sulfinpyrazone
Canadian (sulfinpyrazone alone), 1985	sulfinpyrazone	placebo			-
ticagrelor
DISPERSE-2 (90mg), 2007	ticagrelor	clopidogrel		Exploratory	Negative
PLATO, 2009	ticagrelor	clopidogrel		Low risk of bias	Suggesting	NCT00391872
ticlopidine
Florida UA	ticlopidine	placebo			Negative
STAI, 1990	ticlopidine	control			Suggesting
trapidil
Modena	trapidil	placebo			Suggesting
triflusal
Plaza, 1993	triflusal	placebo			Suggesting
TIM, 2000	triflusal	aspirin			-
UFH
Theroux (heparin+ASP vs ASP), 1988	UFH	control (on top of aspirin)			Suggesting
Theroux (heparin+aspirin vs PBO), 1988	UFH + aspirin	placebo			Suggesting
Theroux (heparin vs PBO), 1988	UFH	placebo			Suggesting
Cohen (ATACS pilot) (heparin vs asp), 1990	UFH, warfarin	aspirin			Negative
Cohen (ATACS pilot) (heparin+aspirin vs asp), 1990	UFH, warfarin	control (on top of aspirin)			Negative
RISC (heparin+aspirin vs ASP), 1990	UFH	control (on top of aspirin)			Negative
RISC (heparin vs PBO), 1990	UFH	placebo			Negative
RISC (ASP+ heparin vs PBO), 1990	UFH + aspirin	placebo			Suggesting
ATACS (Cohen), 1994	UFH, warfarin	control (on top of aspirin)			Negative
Holdright, 1994	UFH	control (on top of aspirin)			Negative
Gurfinkel (UFH+aspririn vs aspirin), 1995	UFH	placebo (on top of aspirin)			Negative
vorapaxar
TRACER, 2011	vorapaxar	placebo (on top standard therapy)		Low risk of bias	-	NCT00527943
warfarin
ATACS (pilot study) warfarin vs aspirin, 1990	warfarin	aspirin			Negative
ATACS (pilot study) (warfarin vs control), 1990	warfarin	control (on top of aspirin)			Negative
ATACS, 1994	warfarin	control (on top of aspirin)			Negative
CARS, 1997	warfarin	control (on top of aspirin)			Negative
Williams, 1997	warfarin	placebo (on top of aspirin)			Negative
OASIS Pilot (phase 1), 1998	warfarin	control (on top of aspirin)			Negative
OASIS Pilot (phase 2), 1998	warfarin	control (on top of aspirin)			Negative
OASIS-2 Warfarin Substudy, 2001	warfarin	control (on top of aspirin)			Negative
Huyhn, 2001	warfarin	placebo (on top of aspirin)			Negative
APRICOT-2, 2002	warfarin	control (on top of aspirin)			Negative
CHAMP, 2002	warfarin	control (on top of aspirin)			Negative
WARIS, 2002	warfarin	control (on top of aspirin)			Suggesting
LoWASA, 2004	warfarin	control (on top of aspirin)			Negative
Zibaeenezhad, 2004	warfarin	control (on top of aspirin)			Negative
ximelagatran
ESTEEM, 2003	ximelagatran	placebo		Exploratory	-
acute myocardial infarction
argatroban
ARGAMI-2, 1998	Argatroban	heparin			-
bivalirudin
HERO, 1997	bivalirudin	heparin		Exploratory	Suggesting
coumadin
ASPECT, 1994	coumadin	placebo			Suggesting
ASPECT-2 (coumadin alone), 2002	coumadin	aspirin			Suggesting
ASPECT-2 (coumadin+ASA vs ASA), 2002	coumadin	control (on top of aspirin)			Negative
dalteparin
FRAMI, 1997	Dalteparin	placebo			-
BIOMACS II, 1999	Dalteparin	placebo			-
ASSENT Plus, 2003	Dalteparin	UFH			Negative
enoxaparin
ASSENT 3, 2001	Enoxaparin	UFH			Suggesting
HART II, 2001	Enoxaparin	UFH			Negative
AMI-SK, 2002	Enoxaparin	placebo			-
Baird, 2002	Enoxaparin	UFH			Negative
ENTIRE-TIMI 2, 2002	Enoxaparin	UFH			Suggesting
ASSENT 3 Plus, 2003	Enoxaparin	UFH			Negative
fondaparinux
MICHELANGELO OASIS-6, 2006	fondaparinux	placebo		Low risk of bias	Suggesting	NCT00064428
hirudin
TIMI 9B, 1996	Hirudin	heparin		Risk of bias	-
HIT-4, 1999	Hirudin	heparin		Exploratory	-
reviparin
CREATE, 2005	Reviparin	placebo			-
UFH
ISIS-2 Pilot, 1987	UFH	no heparin			Negative
ECSG, 1992	UFH	placebo			Negative
OSIRIS, 1992	UFH	placebo			Negative
DUCCS, 1994	UFH	no heparin			Negative
warfarin
CARS (warafrin 3mg), 1997	warfarin	control (on top of aspirin)			Suggesting
CARS (warfarin 1mg), 1997	warfarin	control (on top of aspirin)			Negative
Williams, 1997	warfarin	placebo (on top of aspirin)			Suggesting
WARIS, 1999	warfarin	control (on top of aspirin)			-
WARIS II (warfarin alone), 2002	warfarin	aspirin			Suggesting
APRICOT-2, 2002	warfarin	control (on top of aspirin)			Suggesting
CHAMP, 2002	warfarin	control (on top of aspirin)			Negative
WARIS II (warfarin+ASA), 2002	warfarin	control (on top of aspirin)			Suggesting
Zibaeenezhad, 2004	warfarin	control (on top of aspirin)			Negative
LoWASA, 2004	warfarin	control (on top of aspirin)		Risk of bias	Suggesting
atrial fibrillation
apixaban
phase 2 apixaban	apixaban	warfarin standard dose		Exploratory	-	NCT00787150
AVERROES, 2011	apixaban	aspirin	ineligible for VKA	Low risk of bias	Suggesting	NCT00496769
ARISTOTLE, 2011	apixaban	warfarin standard dose		Low risk of bias	Conclusive	NCT00412984
aspirin
AFASAK (aspirin vs placebo), 1989	aspirin	placebo		Low risk of bias	Negative
AFASAK (aspirin vs warfarin standard dose), 1989	aspirin	warfarin standard dose		Risk of bias	Negative
SPAF (aspirin,warfarin ineligible arm), 1991	aspirin	placebo	ineligible for VKA	Low risk of bias	Negative
SPAF (aspirin , warfarin eligible arm), 1991	aspirin	placebo		Low risk of bias	Suggesting
EAFT, 1993	aspirin	placebo			Negative
SPAF II (aspirin vs warfarin standard dose, age<75), 1994	aspirin	warfarin standard dose		Risk of bias	Negative
SPAF II (aspirin vs warfarin standard dose, age>75), 1994	aspirin	warfarin standard dose		Risk of bias	Negative
AFASAK II (aspirin vs warfarin low dose), 1998	aspirin	warfarin low dose		Risk of bias	Negative
AFASAK II (aspirin vs warfarin standard dose), 1998	aspirin	warfarin standard dose		Risk of bias	Negative
LASAF(aspirin vs no treatment), 1999	aspirin	control			-
PATAF (vs coumadin low dose), 1999	aspirin	coumadin low dose		Risk of bias	Negative
PATAF (vs coumadin standard dose), 1999	aspirin	coumadin standard dose		Risk of bias	Negative
FFAACS , 2001	aspirin	placebo (on top fluidione)			Negative
BAFTA (aspirin vs warfarin standard dose) ongoing	aspirin	warfarin standard dose			-
clopidogrel
ACTIVE W, 2006	aspirin + clopidogrel	anticoagulant		Risk of bias	Suggesting	NCT00243178
ACTIVE A, 2009	aspirin + clopidogrel	aspirin		Low risk of bias	Suggesting	NCT00249873
coumadin
PATAF (coumadin low dose vs coumadin standard dose), 1999	coumadin low dose	coumadin standard dose		Risk of bias	Negative
dabigatran
RE-LY 150mg (2nd prevention subgroup)	dabigatran 150mg	warfarin		Exploratory	Suggesting
phase 2 dabigatran	dabigatran	warfarin standard dose		Exploratory	-	NCT01136408
PETRO (150mg), 2007	dabigatran 150mg	warfarin standard dose		Exploratory	-
RE-LY (150mg), 2009	dabigatran 150mg	warfarin standard dose		Risk of bias	Suggesting	NCT00262600
RE-LY (110mg), 2009	dabigatran 110mg	warfarin standard dose		Risk of bias	Suggesting	NCT00262600
RE-LY 110mg (2nd prevention subgroup) , 2010	dabigatran 100mg	warfarin		Exploratory	Suggesting
edoxaban
Weitz (edoxaban phase 2)	edoxaban	warfarin standard dose		Exploratory	-	NCT00504556
phase 2 edoxaban	edoxaban	warfarin standard dose		Exploratory	-	NCT00806624
ENGAGE-AF TIMI 48 High dose, 2013	edoxaban high dose	warfarin standard dose		Low risk of bias	Suggesting	NCT00781391
idraparinux
AMADEUS, 2008	idraparinux	warfarin standard dose		Risk of bias	Negative	NCT00070655
idraparinux BOREALIS-AF ongoing	idraparinux	warfarin standard dose			-	NCT00580216
rivaroxaban
ROCKET-AF, 2010	rivaroxaban	warfarin standard dose		Low risk of bias	Suggesting	NCT00403767
ROCKET (2nd prevention subgroup) , 2011	rivaroxaban	warfarin			Negative
ROCKET J ongoing	rivaroxaban	warfarin standard dose			-	NCT00494871
triflusal
NASPEAF (triflusal vs coumadin standard dose)), 2004	triflusal	coumadin standard dose		Risk of bias	Negative
warfarin
AFASAK (warfarin standard dose vs control), 1989	warfarin standard dose	control		Risk of bias	Suggesting
BAATAF (warfarin vs no treatment), 1990	warfarin low dose	control		Risk of bias	Suggesting	NCT00000517
SPAF (warfarin standard dose), 1991	warfarin standard dose	control		Risk of bias	Suggesting
CAFA, 1991	warfarin standard dose	placebo		Low risk of bias	Negative
SPINAF (warfarin vs placebo), 1992	warfarin low dose	placebo		Low risk of bias	Negative
SPAF III, 1996	warfarin + aspirin	warfarin standard dose		Risk of bias	-
AFASAK II (warfarin low dose vs warfarin standard dose), 1998	warfarin low dose	warfarin standard dose		Risk of bias	Negative
AFASAK II (warfarin low dose+aspirin vs warfarin standard dose), 1998	warfarin + aspirin	warfarin standard dose		Risk of bias	Negative
MWNAF, 1998	warfarin low dose	warfarin standard dose		Risk of bias	Negative
SAFT(warfarin low dose + aspirin vs no treatment), 2003	warfarin low dose + aspirin	control		Risk of bias	Negative
ximelagatran
SPORTIF II (ximelagatran vs warfarin standard dose), 2002	ximelagatran	warfarin standard dose		Risk of bias	-
SPORTIF III, 2003	ximelagatran	warfarin standard dose		Risk of bias	Suggesting
SPORTIF V, 2005	ximelagatran	warfarin standard dose		Low risk of bias	Suggesting
heart failure
aspirin
Barzizza (ASA), 1993	aspirin	placebo		Exploratory	-
WASH (aspirin), 2004	aspirin	no treatment			Negative
clopidogrel
WATCH (clopidogrel vs aspirin) ongoing	clopidogrel	aspirin			-
enoxaparin
THE-PRINCE (Kleber), 2003	enoxaparin	UFH			-
rivaroxaban
COMMANDER HF, 2018	rivaroxaban	placebo			Negative	NCT01877915
warfarin
Barzizza (warfarin), 1993	warfarin	placebo			-
WASH (warfarin), 2004	warfarin	no treatment			Negative
HELAS (warfarin vs aspirin), 2006	warfarin	aspirin			-
HELAS (warfarin vs placebo), 2006	warfarin	placebo			-
WATCH (warfarin vs aspirin), 2009	warfarin	aspirin			Suggesting	NCT00007683
percutaneous coronary intervention
abciximab
EPIC (with infusion), 1994	Abciximab	placebo			-
Simoons, 1994	Abciximab	placebo			-
EPILOG, 1997	Abciximab	placebo			-
CAPTURE, 1997	Abciximab	placebo			-
RAPPORT, 1998	Abciximab	placebo			-
EPISTENT, 1998	Abciximab	placebo			-
ERASER, 1999	Abciximab	placebo			-
ISAR-2, 2000	Abciximab	placebo			-
ADMIRAL, 2001	Abciximab	placebo			-
Kini, 2001	Abciximab	placebo			-
CADILLAC, 2002	Abciximab	placebo			-
Petronio, 2002	Abciximab	placebo			-
Tamburino, 2002	Abciximab	placebo			-
aspirin
Taylor (Perth), 1991	aspirin	placebo			Negative
M-HEART II (aspirin), 1995	aspirin	placebo			Negative
bivalirudin
ARMYDA BIVALVE	bivalirudin	UFH			-
BAT (Bittl), 1995	bivalirudin	UFH		Low risk of bias	Suggesting
Kleiman, 2002	bivalirudin + eptifibatide	heparin + GP2b3a inhibitors		Exploratory	-
REPLACE-2, 2003	bivalirudin	heparin + GP2b3a inhibitors			-
REPLACE-1, 2004	bivalirudin	UFH		Exploratory	Negative
ACUITY (Stone) (bivalirudin alone), 2006	bivalirudin	heparin + GP2b3a inhibitors		Risk of bias	-	NCT00093158
HORIZONS-AMI (Stone), 2008	bivalirudin	heparin + GP2b3a inhibitors		Risk of bias	Suggesting	NCT00433966
ISAR-REACT 3, 2008	bivalirudin	UFH		Low risk of bias	-	NCT00262054
NAPLES (Tavano), 2009	bivalirudin	UFH plus tirofiban		Risk of bias	Suggesting
BRAVE-4 ongoing	Prasugrel and Bivalirudin	Clopidogrel and Heparin			-	NCT00976092
cangrelor
CHAMPION-PCI, 2009	cangrelor up front	clopidogrel up front		Low risk of bias	Negative	NCT00305162
CHAMPION-PLATFORM, 2009	cangrelor up front	delayed clopidogrel			Negative	NCT00385138
CHAMPION PHOENIX, 2013	cangrelor	clopidogrel		Low risk of bias	Suggesting	NCT01156571
cilostazol
Kunishima, 1997	cilostazol	aspirin			Negative
Sekiya, 1998	cilostazol + aspirin	aspirin			Negative
Ochiai, 1999	cilostazol + aspirin	ticlopidine + aspirin			Negative
Park, 1999	cilostazol + aspirin	ticlopidine + aspirin			Negative
Yoon, 1999	cilostazol + aspirin	ticlopidine + aspirin			Negative
Kozuma, 2001	cilostazol + aspirin	ticlopidine + aspirin			Negative
Kamishirado, 2002	cilostazol + aspirin	ticlopidine + aspirin			Negative
clopidogrel
Müller, 2000	clopidogrel + aspirin	ticlopidine + aspirin			Negative
CLASSICS, 2000	clopidogrel + aspirin	ticlopidine + aspirin			Negative
TOPPS, 2001	clopidogrel + aspirin	ticlopidine + aspirin			Negative
Piamsomboon, 2001	clopidogrel + aspirin	ticlopidine + aspirin			Negative
GRAVITAS, 2011	high-dose clopidogrel	normal-dose clopidogrel		Risk of bias	Negative	NCT00645918
dalteparin
Natarajan (without antiGp2b3a), 2003	dalteparin	UFH			-
Natarajan (+ antiGp2b3a), 2003	dalteparin	UFH + anti Gp2b3a			-
dipyridamol
Schwartz (Toronto), 1988	aspirin + dipyridamol	placebo			Suggesting
Mayo-PTCA, 1989	aspirin + dipyridamol	placebo			Negative
Nye (Dunedin), 1990	aspirin + dipyridamol	placebo			Negative
White (aspirin+dipiridamol), 1991	aspirin + dipyridamol	placebo			Negative
elinogrel
INNOVATE PCI	elinogrel	clopidogrel			-	NCT00751231
enoxaparin
Rabah, 1999	enoxaparin	UFH		Exploratory	Negative
Dudek, 2000	enoxaparin	UFH			Negative
Dudek b (enox alone), 2000	enoxaparin	UFH			-
Galeote, 2001	enoxaparin	UFH			Negative
Drozd, 2001	enoxaparin	UFH			Negative
Dubek b (+abciximal), 2001	enoxaparin+abciximab	UFH			-
CRUISE, 2003	enoxaparin	UFH		Exploratory	Negative
STEEPLE, 2006	enoxaparin	UFH		Risk of bias	-	NCT00077844
ATOLL, 2010	enoxaparin	UFH		Risk of bias	-
STREAM ongoing	enoxaparin	unfractionated heparin			-	NCT00882635
eptifibatide
IMPACT (4h), 1995	Eptifibatide	placebo			-
Harrington, 1995	Eptifibatide	placebo			-
IMPACT-II (0.5µg), 1997	Eptifibatide	placebo			-
ESPRIT, 2000	Eptifibatide	placebo			-
fondaparinux
SWITCH III ongoing	fondaparinux	unfractionated heparin or bivalirudin			-	NCT00464087
prasugrel
JUMBO-TIMI 26, 2005	prasugrel	clopidogrel		Exploratory	Negative
TRITOM TIMI 38 (PCI subgroup), 2009	prasugrel	clopidogrel			-
TRIGGER-PCI ongoing	prasugrel	Clopidogrel			-	NCT00910299
reviparin
REDUCE, 1996	reviparin	UFH		Low risk of bias	Suggesting
sulotroban
M-HEART II (sulotroban), 1995	sulotroban	placebo			-
ticlopidine
TACT, 1990	ticlopidine	placebo			Negative
White (ticlopidine), 1991	ticlopidine	placebo			-
Hall, 1996	ticlopidine + aspirin	aspirin			Negative
ISAR, 1996	ticlopidine + aspirin	coumadin + aspirin			Suggesting
STARS (vs aspirin), 1998	ticlopidine + aspirin	aspirin			Suggesting
FANTASTIC, 1998	ticlopidine + aspirin	coumadin + aspirin			Negative
MATTIS, 1998	ticlopidine + aspirin	coumadin + aspirin			Negative
STARS (vs coumadin+asp), 1998	ticlopidine + aspirin	coumadin + aspirin			Suggesting
Foussas, 2000	ticlopidine + aspirin	coumadin + aspirin			Suggesting
tirofiban
Kereiakis, 1996	Tirofiban	placebo			-
RESTORE, 1997	Tirofiban	placebo			-
peripheral vascular diseases
acenocoumarol
APIC, 1989	acenocoumarol	placebo			-
aspirin
Lassila R, 1991	aspirin	contrôle			-
BOA, 2000	aspirin				-
CLIPS, 2007	aspirin	placebo		Low risk of bias	Suggesting
clopidogrel
AFFIRM ongoing	clopidogrel				-
ticlopidine
Becquemin, 1997	ticlopidine	contrôle			-
UFH
Tesi, 1989	HNF	placebo			-
Antonicelli, 1999	HNF	placebo			-
warfarin
Sarac, 1998	warfarin	contrôle			-
Johnson, 2002	warfarin	contrôle			-
post acute coronary syndromes
dabigatran
REDEEM, 2009	dabigatran	placebo			Negative	NCT00621855
post myocardial infarction
dabigatran
REDEEM, 2009	dabigatran	placebo			Negative	NCT00621855
pulmonary embolism
apixaban
AMPLIFY-EXT 2.5mg, 2012	apixaban 2.5mg	discontinuation			Suggesting	NCT00633893
AMPLIFY-EXT 5mg, 2012	apixaban 5mg	discontinuation			Suggesting	NCT00633893
AMPLIFY, 2013	apixaban (without LMWH)	LMWH/VKA		Low risk of bias	Suggesting	NCT00643201
Certoparin
Certoparin-Study Group sub group, 1998	Certoparin	unfractionated heparin		Exploratory	Negative
dalteparin
Kuijer, 1995	Dalteparin	unfractionated heparin			Negative
Meyer, 1995	Dalteparin	unfractionated heparin			Negative
enoxaparin
PREPIC, 1998	Enoxaparin	unfractionated heparin		Risk of bias	Negative
Merli sub group, 2001	Enoxaparin	unfractionated heparin		Exploratory	Negative
fondaparinux
MATISSE PE, 2003	fondaparinux	heparin		Risk of bias	Negative
idraparinux
VanGogh PE, 2007	idraparinux (without heparin)	heparin/VKA		Risk of bias	Negative	NCT00062803
nadroparin
European multicentre study, 1991	Nadroparin	unfractionated heparin		Risk of bias	Negative
Prandoni sub-group, 1992	Nadroparin	unfractionated heparin		Exploratory	Negative
Thery, 1992	Nadroparin	unfractionated heparin		Exploratory	Negative
reviparin
COLOMBUS sub group, 1997	Reviparin	unfractionated heparin		Exploratory	Negative
rivaroxaban
Einstein-PE Evaluation, 2012	rivaroxaban (without LMWH)	LMWH/VKA		Risk of bias	-	NCT00439777
tinzaparin
ACTSG (Hull) sub-group, 1992	Tinzaparin	unfractionated heparin		Exploratory	Negative
THESEE, 1997	Tinzaparin	unfractionated heparin		Risk of bias	Negative
Campbell, 1998	Tinzaparin	unfractionated heparin			Negative
stable angina
aspirin
SAPAT, 1992	aspirin	placebo		Low risk of bias	Suggesting
clopidogrel
ASCET	clopidogrel	aspirin		Risk of bias	Negative	NCT00222261
dipyridamol
Foulds, 1960	dipyridamol	placebo		Exploratory	-
Zion, 1961	dipyridamol	placebo		Exploratory	-
Dewar, 1961	dipyridamol	placebo		Exploratory	-
Kinsella, 1962	dipyridamol	placebo		Exploratory	-
Leiberman, 1964	dipyridamol	placebo		Exploratory	-
Neumann, 1964	dipyridamol	placebo		Exploratory	-
Atlanta (Sbar), 1967	dipyridamol	control		Exploratory	Negative
Becker, 1967	dipyridamol	control		Exploratory	Negative
Wirecki, 1967	dipyridamol	control		Exploratory	Negative
Igloe, 1970	dipyridamol	placebo		Exploratory	-
ticlopidine
Berglund, 1985	ticlopidine	placebo		Exploratory	Negative
stent
cilostazol
Kunishima, 1997	cilostazol	aspirin			Negative
Sekiya, 1998	cilostazol + aspirin	aspirin			Negative
Ochiai, 1999	cilostazol + aspirin	ticlopidine + aspirin			Negative
Park, 1999	cilostazol + aspirin	ticlopidine + aspirin			Negative
Yoon, 1999	cilostazol + aspirin	ticlopidine + aspirin			Negative
Kozuma, 2001	cilostazol + aspirin	ticlopidine + aspirin			Negative
Kamishirado, 2002	cilostazol + aspirin	ticlopidine + aspirin			Negative
clopidogrel
Müller, 2000	clopidogrel + aspirin	ticlopidine + aspirin			Negative
CLASSICS, 2000	clopidogrel + aspirin	ticlopidine + aspirin			Negative
TOPPS, 2001	clopidogrel + aspirin	ticlopidine + aspirin			Negative
Piamsomboon, 2001	clopidogrel + aspirin	ticlopidine + aspirin			Negative
REAL-LATE, ZEST-LATE, 2010	clopidogrel+aspirin	aspirin			Negative	NCT00484926
GRAVITAS, 2011	high-dose clopidogrel	normal-dose clopidogrel		Risk of bias	Negative	NCT00645918
ticlopidine
Hall, 1996	ticlopidine + aspirin	aspirin			Negative
ISAR, 1996	ticlopidine + aspirin	coumadin + aspirin			Suggesting
STARS (vs aspirin), 1998	ticlopidine + aspirin	aspirin			Suggesting
FANTASTIC, 1998	ticlopidine + aspirin	coumadin + aspirin			Negative
MATTIS, 1998	ticlopidine + aspirin	coumadin + aspirin			Negative
STARS (vs coumadin+asp), 1998	ticlopidine + aspirin	coumadin + aspirin			Suggesting
Foussas, 2000	ticlopidine + aspirin	coumadin + aspirin			Suggesting
superficial thrombophlebitis
candesartan
Andreozzi (200 vs 100), 1996	desmin 200	desmin 100			-
Andreozzi (desmin SC vs 100), 1996	desmin SC	desmin 100			-
coumadin
Belcaro (coumadin vs low dose hep), 1999	coumadin	low dose heparin			-
defibrotide
Belcaro, 1990	defibrotide	low dose heparin			-
Diclofenac
Nocker (diclofenac), 1991	Diclofenac	placebo			-
enoxaparin
Stenox (enoxaparin 40mg), 2003	enoxaparin	placebo			-
STENOX (enoxaparin 1.5mg/hg), 2003	enoxaparin	placebo			-
fondaparinux
CALISTO, 2010	fondaparinux	placebo		Low risk of bias	Suggesting	NCT00443053
heparin
Belcaro (hep vs no hep), 1989	heparin	no treatment			-
Belcaro (hep vs defibrotide), 1990	heparin				-
Marchiori, 2002	heparin	low dose UFH			-
Katzenschlager, 2003	liposomal heparin-spraygel	enoxaparin			-
Gorski, 2005	heparin spraygel	clexane			-
nadroparin
Titon (nadroparin 0.6ml vs naproxen), 1994	nadroparin	naproxene			-
Titon (nadroparin 61.5 IU anti-Xa/kg vs naproxen), 1994	nadroparin	naproxene			-
Vesalio, 2005	nadroparin fixed-dose	nadroparin weight-adjusted			-
Nimesulide
Ferrari, 1992	Nimesulide	diclofenac			-
UFH
Belcaro (prophylactic UFH vs no), 1999	Prophylactic UFH	no treatment			-
thrombosis prevention
acenocoumarol
van Geloven, 1977	Acenocoumarol	unfractionated heparin			-
Hamulyak, 1994	Acenocoumarol	Nadroparin			Negative
Samama, 2001	Acenocoumarol	Reviparin			Negative
apixaban
APROPOS 2.5mg, 2007	apixaban	enoxaparin (US regimen)	knee surgery	Exploratory	Negative	NCT00097357
ADVANCE 3, 2010	apixaban	enoxaparin	hip surgery	Low risk of bias	Suggesting	NCT00423319
ADVANCE 2, 2010	apixaban	enoxaparin (europe regimen)	knee surgery	Low risk of bias	Suggesting	NCT00452530
ADOPT, 2011	apixaban	enoxaparin	medical patients	Low risk of bias	Suggesting	NCT00457002
CV185-027 ongoing	apixaban	placebo			-	NCT00320255
ardeparin
Godwin, 1993	ardeparin	unfractionated heparin	abdominal surgery		-
Levine, 1996	ardeparin	placebo	knee surgery		Suggesting
Heit, 2000	out of hospital Ardeparin	standard prophylaxis			Negative
aspirin
<a href='javascript:viewTrial(3652)' class='popover-interpretation' style='color: gray;' sort='' data-toggle='popover' data-placement='right' data-html='true' data-trigger='hover' container='body' data-content="<div id='trial3652' style='color: black; '> MRC, 1972 aspirin vs placebo Low risk of bias <table class='table table-condensed' style='font-size:

antithrombotics Description Results

Group by...

MRC, 1972 aspirin vs placebo Low risk of bias

Digital discoveries

antithrombotics
Description Results